Both GLP|1 Receptor Agonists and Bariatric Surgery Lower the Risk ...

Both GLP-1 Receptor Agonists and Bariatric Surgery Lower the Risk ...

For people with a BMI of 35 kg/m2 or higher, both GLP-1RAs and bariatric surgery appear to lower the risk of developing an obesity-related ...

Bariatric Surgery vs Glucagon-Like Peptide-1 Receptor Agonists ...

Findings In this cohort study comprising 6070 patients, among individuals with a diabetes duration of 10 years or less, BMS was associated with ...

Comparative risk of obesity-related cancer with glucagon-like ...

Conclusions: GLP-1 RA was associated with a lower risk of obesity-related cancer comparable to bariatric surgery in patients with BMI ≥ 35. GLP- ...

Study Finds Bariatric Surgery Declined with Rise in GLP-1 Drugs to ...

Researchers documented a 132.6% increase in patients prescribed GLP-1 drugs between 2022 and 2023, and a 25.6% decrease in patients undergoing ...

Glucagon-like peptide-1 receptor agonists for post-bariatric surgery ...

Both primary and revisional surgeries exhibited reductions in body mass index (BMI); emphasizing the overall efficacy of GLP-1 RAs. The collective evidence ...

Weight loss between glucagon-like peptide-1 receptor agonists and ...

In adults with obesity, bariatric surgery still confers the highest reductions in weight and BMI but confers similar effects in glycemic control when ...

GLP-1 RAs Reduce Obesity-Related Cancers at a Rate Similar to ...

Glucagon-like peptide-1 receptor agonists reduce obesity-related cancer risk ... Both surgery and GLP-1 therapy had superior all-cause ...

Post metabolic bariatric surgery weight regain: the importance of ...

There is growing evidence that GLP-1-receptor agonist (GLP-1-RA) use in patients who regained weight after bariatric surgery has resulted in ...

Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor ...

This study suggests that BMS was associated with greater reduced mortality compared with GLP-1RAs among individuals with a diabetes duration of 10 years or ...

Metabolic Bariatric Surgery in the Era of GLP-1 Receptor Agonists ...

This cross-sectional study of privately insured patients found a more than 2-fold increase in use of GLP-1 RAs as antiobesity medications from 2022 to 2023.

Adverse event comparison between glucagon‐like peptide‐1 ...

GLP-1RA AOMs do not appear to lead to a heightened risk of AEs in patients who have previously undergone bariatric surgery. While our study ...

Glucose-lowering drugs reduce risk for obesity-related cancers

“Both glucagon-like peptide-1 receptor agonist therapy and bariatric surgery reduced the risk [for] weight-related cancer as compared [with] ...

Cardiovascular and diabetes outcomes among patients with obesity ...

Compared with glucagon-like peptide 1 receptor agonist treatment, metabolic bariatric surgery is associated with superior metabolic outcomes and ...

Bariatric Surgery Beats GLP-1 RAs in Reducing Mortality Risk

Bariatric metabolic surgery led to 62% greater reductions in mortality than GLP-1 receptor agonists in patients with obesity and diabetes ...

Anti-obesity drugs are closing the gap between dieting and bariatric ...

GLP-1 receptor agonist medications were originally developed to treat type 2 diabetes and were found to cause weight loss while also decreasing the risk of ...

Major adverse cardiovascular events among patients with type-2 ...

Glucagon-like Peptide-1 receptor agonists (GLP-1 RA) and metabolic and bariatric surgery (MBS) both improve cardiovascular outcomes in ...

Weighing the Options: Bariatric Surgery vs. Weight Loss Drugs

Recent studies favor bariatric surgery for overall weight loss and Body Mass Index (BMI) reduction, but show that both surgery and GLP-1 ...

Exposure to GLP-1 Receptor Agonist and Bariatric Surgery Use on ...

Exposure to medical weight loss interventions led to higher GLP-1 agonist policy support. However, exposure also indirectly led to lower ...

What Is Best for Weight Loss? A Comparative Review of the Safety ...

While bariatric surgery showed superior efficacy, it also carried a higher risk of complications. In contrast, semaglutide presented a ...

Ozempic-Like GLP-1 Drugs Led to Weight Loss After Bariatric Surgery

New research has found that glucagon-like peptide-1 (GLP-1) receptor antagonist drugs may improve outcomes in individuals who underwent bariatric surgery.